NOVO-DIPIRADOL TAB 75MG TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

DIPYRIDAMOLE

Saatavilla:

NOVOPHARM LIMITED

ATC-koodi:

B01AC07

INN (Kansainvälinen yleisnimi):

DIPYRIDAMOLE

Annos:

75MG

Lääkemuoto:

TABLET

Koostumus:

DIPYRIDAMOLE 75MG

Antoreitti:

ORAL

Kpl paketissa:

100/500

Prescription tyyppi:

Prescription

Terapeuttinen alue:

MISCELLANEOUS VASODILATATING AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0106621003; AHFS:

Valtuutuksen tilan:

CANCELLED POST MARKET

Valtuutus päivämäärä:

2005-08-10

Valmisteyhteenveto

PRODUCT MONOGRAPH
Pr
NOVO-DIPIRADOL (dipyridamole) 25, 50, 75, 100 mg Tablets
Pr
DIPYRIDAMOLE FOR INJECTION (dipyridamole) 5 mg/mL, USP
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Novopharm Limited
Date of Preparation:
30 Novopharm Court
October 26, 2006
Toronto, Ontario
M1B 2K9
Control No. 107491
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS...........................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
8
DOSAGE AND
ADMINISTRATION.......................................................................................
9
OVERDOSAGE
.........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 10
STORAGE AND
STABILITY.................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
13
PHARMACEUTICAL
INFORMATION.........................................................